386 related articles for article (PubMed ID: 25796589)
21. Anti-factor H antibody-positive C3 glomerulonephritis secondary to poststreptococcal acute glomerulonephritis with diabetic nephropathy.
Oba Y; Mizuno H; Taneda S; Sawai T; Oda T; Ikuma D; Yamanouchi M; Suwabe T; Kono K; Kinowaki K; Ohashi K; Sawa N; Ubara Y
CEN Case Rep; 2024 Apr; 13(2):110-116. PubMed ID: 37452997
[TBL] [Abstract][Full Text] [Related]
22. C3 glomerulopathy.
Servais A; Noël LH; Frémeaux-Bacchi V; Lesavre P
Contrib Nephrol; 2013; 181():185-93. PubMed ID: 23689580
[TBL] [Abstract][Full Text] [Related]
23. Eculizumab reversed severe distal ischemic syndrome and glomerulonephritis with isolated C3 deposits associated with anti-factor H autoantibodies: a case report.
Deshayes S; Martin Silva N; Chatelet V; Chantepie S; Le Quintrec M; Comoz F; Bridoux F; Dragon-Durey MA; Aouba A
Clin Rheumatol; 2018 Apr; 37(4):1119-1122. PubMed ID: 29516279
[TBL] [Abstract][Full Text] [Related]
24. Utilizing therapeutic drug monitoring to optimize therapy with eculizumab and mycophenolate mofetil in a child with C3 glomerulonephritis.
Riedl Khursigara M; Chung E; Tjon J; Noone D; Chami R; Licht C; Teoh CW
Pediatr Nephrol; 2023 Oct; 38(10):3483-3487. PubMed ID: 36884075
[TBL] [Abstract][Full Text] [Related]
25. Treating C3 glomerulopathy with eculizumab.
Welte T; Arnold F; Kappes J; Seidl M; Häffner K; Bergmann C; Walz G; Neumann-Haefelin E
BMC Nephrol; 2018 Jan; 19(1):7. PubMed ID: 29329521
[TBL] [Abstract][Full Text] [Related]
26. De novo C3 glomerulonephritis in a renal allograft.
Nahm JH; Song SH; Kim YS; Cheong HI; Lim BJ; Kim BS; Jeong HJ
Ultrastruct Pathol; 2016; 40(2):112-5. PubMed ID: 26986539
[TBL] [Abstract][Full Text] [Related]
27. Monoclonal immunoglobulin mediates complement activation in monoclonal gammopathy associated-C3 glomerulonephritis.
Li LL; Li ZY; Wang SX; Yu XJ; Tan Y; Wang Y; Yu F; Zhao MH
BMC Nephrol; 2019 Dec; 20(1):459. PubMed ID: 31823738
[TBL] [Abstract][Full Text] [Related]
28. Rituximab fails where eculizumab restores renal function in C3nef-related DDD.
Rousset-Rouvière C; Cailliez M; Garaix F; Bruno D; Laurent D; Tsimaratos M
Pediatr Nephrol; 2014 Jun; 29(6):1107-11. PubMed ID: 24408225
[TBL] [Abstract][Full Text] [Related]
29. C3 glomerulopathy in children: Is there still a place for anti-cellular immunosuppression?
Kojc N; Bahovec A; Levart TK
Nephrology (Carlton); 2019 Feb; 24(2):188-194. PubMed ID: 30393898
[TBL] [Abstract][Full Text] [Related]
30. Blockade of C5 in Severe Acute Postinfectious Glomerulonephritis Associated With Anti-Factor H Autoantibody.
Chehade H; Rotman S; Frémeaux-Bacchi V; Aubert V; Sadallah S; Sifaki L; Salomon R; Pascual M
Am J Kidney Dis; 2016 Dec; 68(6):944-948. PubMed ID: 27683044
[TBL] [Abstract][Full Text] [Related]
31. C3 glomerulopathy and current dilemmas.
Ito N; Ohashi R; Nagata M
Clin Exp Nephrol; 2017 Aug; 21(4):541-551. PubMed ID: 27878657
[TBL] [Abstract][Full Text] [Related]
32. C3 glomerulopathy: A new complement-based entity.
de Lorenzo A; Tallón S; Hernández-Sevillano B; de Arriba G
Rev Clin Esp (Barc); 2014; 214(5):266-74. PubMed ID: 24576419
[TBL] [Abstract][Full Text] [Related]
33. Likely Recurrence of C3 Glomerulonephritis in Kidney Transplantation: An Entity to Bear in Mind: Case Report.
Perea-Ortega L; León-Fradejas M; Alonso-Titos J; Cabello-Díaz M; Toledo-Rojas R; Sola-Moyano E; Martín-Reyes G; López-Jiménez V; Burgos-Rodríguez D; Hernández-Marrero D
Transplant Proc; 2015 Nov; 47(9):2669-71. PubMed ID: 26680069
[TBL] [Abstract][Full Text] [Related]
34. Kidney Transplantation in C3 Glomerulopathy: A Case Series.
Regunathan-Shenk R; Avasare RS; Ahn W; Canetta PA; Cohen DJ; Appel GB; Bomback AS
Am J Kidney Dis; 2019 Mar; 73(3):316-323. PubMed ID: 30413277
[TBL] [Abstract][Full Text] [Related]
35. [Characteristics of pediatric C3 glomerulopathy with decreased factor H in 3 cases].
He RJ; Xiao HJ; Wang SX; Guan N; Yao Y; Ding J
Zhonghua Er Ke Za Zhi; 2012 Dec; 50(12):939-43. PubMed ID: 23324154
[TBL] [Abstract][Full Text] [Related]
36. Proliferative glomerulonephritis with monoclonal immunoglobulin G deposits complicated by immunoglobulin A nephropathy in the renal allograft.
Sawada A; Kawanishi K; Horita S; Koike J; Honda K; Ochi A; Komoda M; Tanaka Y; Unagami K; Okumi M; Shimizu T; Ishida H; Tanabe K; Nagashima Y; Nitta K
Nephrology (Carlton); 2016 Jul; 21 Suppl 1():48-52. PubMed ID: 26971743
[TBL] [Abstract][Full Text] [Related]
37. Immunosuppressive Treatment in C3 Glomerulopathy: Is it Really Effective?
Caliskan Y; Torun ES; Tiryaki TO; Oruc A; Ozluk Y; Akgul SU; Temurhan S; Oztop N; Kilicaslan I; Sever MS
Am J Nephrol; 2017; 46(2):96-107. PubMed ID: 28700996
[TBL] [Abstract][Full Text] [Related]
38. Eculizumab for treatment of rapidly progressive C3 glomerulopathy.
Le Quintrec M; Lionet A; Kandel C; Bourdon F; Gnemmi V; Colombat M; Goujon JM; Frémeaux-Bacchi V; Fakhouri F
Am J Kidney Dis; 2015 Mar; 65(3):484-9. PubMed ID: 25530108
[TBL] [Abstract][Full Text] [Related]
39. Evolution of immunoglobulin deposition in C3-dominant membranoproliferative glomerulopathy.
Kerns E; Rozansky D; Troxell ML
Pediatr Nephrol; 2013 Nov; 28(11):2227-31. PubMed ID: 23892798
[TBL] [Abstract][Full Text] [Related]
40. Eculizumab for dense deposit disease and C3 glomerulonephritis.
Bomback AS; Smith RJ; Barile GR; Zhang Y; Heher EC; Herlitz L; Stokes MB; Markowitz GS; D'Agati VD; Canetta PA; Radhakrishnan J; Appel GB
Clin J Am Soc Nephrol; 2012 May; 7(5):748-56. PubMed ID: 22403278
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
